Previous close | 1.6000 |
Open | 5.6442 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.6000 - 1.6000 |
52-week range | 0.3530 - 1.6000 |
Volume | |
Avg. volume | 3,695 |
Market cap | 394,955 |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LYON, France, November 08, 2023--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2023.
LYON, France, October 12, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at two upcoming investor conferences.
LYON, France, October 02, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.